# Aztreonam Lysine for Pseudomonas Infection Eradication Study

> **NCT01375049** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 105 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Aztreonam for Inhalation Solution (AZLI)

## Key facts

- **NCT ID:** NCT01375049
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2014-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01375049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01375049, "Aztreonam Lysine for Pseudomonas Infection Eradication Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01375049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*